Expert Perspectives on
the Role of BTK Inhibitors in B-Cell Malignancies: What Managed Care
Needs to Know for Improved Clinical and Economic Outcomes
A continuing medical
education activity provided by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management
of B-Cell malignancies with BTK inhibitors, including how
to translate the
most recent data into clinical and administrative
practice.
These are archives of live webinars held between April 1 to April
22, 2020.
If you participated in any of the live webinars, you are not
eligible
to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
Each session has its own specific valid dates
This series is supported by educational
grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company
and Janssen Biotech, Inc.
Audience:
This activity is intended for healthcare professionals practicing in managed
care environments.
Instructions for CME/CNE: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
certificate.
Description:
Bruton's tyrosine kinase (BTK) is an enzyme that in humans is encoded by the BTK
gene. BTK is abundantly expressed and constitutively active in the pathogenesis
of B cell hematological malignancies. Therefore, BTK is considered as an
attractive target for treatment of B-cell malignancies. These options, known as
BTK inhibitors, have changed the treatment paradigm in several different B-cell
malignancies in recent years. These agents differ in dosing, efficacy, and
toxicities, and as these options for B-cell malignancies grow, it is essential
to understand their clinical and economic role in the treatment paradigm to
offer patients the safest and most efficacious treatment, while also controlling
costs. |